新型生物标志物与心脏手术后1年再入院或死亡的相关性
研究纳入8个医学中心2004至2007年间1047例孤立性冠状动脉旁路移植术后存活出院患者,检测血浆可溶性ST2、半乳糖凝集素-3和N末端脑钠肽前体水平,采用Kaplan-Meier估计和Cox比例风险模型分析其与1年再入院或死亡的关联,并校正胸外科医师学会30天再入院模型中的协变量。结果显示,术后半乳糖凝集素-3和N末端脑钠肽前体高于中位水平均与1年再入院或死亡显著相关。
要点
- 术后半乳糖凝集素-3高于中位水平与1年再入院或死亡相关,风险比1.40(95%CI 1.08-1.80,P=0.010)。
- 术后N末端脑钠肽前体高于中位水平与1年再入院或死亡相关,风险比1.42(95%CI 1.07-1.87,P=0.014)。
- 检测这些生物标志物可能有助于在出院前识别再入院或死亡风险最高的患者。
核心结论
- 在心脏手术患者中,新型心脏生物标志物与再入院或死亡相关,且独立于已确立的危险因素。
- 检测这些生物标志物可能提高在出院前识别再入院或死亡最高风险患者的能力,并据此分配资源,同时根据患者的生物标志物谱实施个性化医疗策略。
研究设计与样本
- 研究为队列研究,纳入北方新英格兰心血管疾病研究组8个医学中心2004至2007年间1047例孤立性冠状动脉旁路移植术后存活出院患者,检测血浆生物标志物。
- 采用Kaplan-Meier估计和Cox比例风险模型评估术前和术后生物标志物与1年再入院或死亡的关联,并校正胸外科医师学会30天再入院模型中的协变量。
主要发现
- 中位随访时间为365天。
- 校正已确立危险因素后,术后半乳糖凝集素-3高于中位水平(中位数10.35 ng/mL)与1年再入院或死亡显著相关,风险比1.40(95%CI 1.08-1.80,P=0.010)。
- 术后N末端脑钠肽前体高于中位水平(中位数15.21 ng/mL)与1年再入院或死亡显著相关,风险比1.42(95%CI 1.07-1.87,P=0.014)。
临床怎么用
- 作者认为,检测这些生物标志物可能提高在出院前识别再入院或死亡最高风险患者的能力。
- 作者认为,这将允许据此分配资源,同时根据患者的生物标志物谱实施个性化医疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel cardiac biomarkers including soluble suppression of tumorigenicity 2, galectin-3, and the N-terminal prohormone of brain natriuretic peptide may be associated with long-term adverse outcomes after cardiac surgery. We sought to measure the association between cardiac biomarker levels and 1-year hospital readmission or mortality. METHODS: Plasma biomarkers from 1,047 patients discharged alive after isolated coronary artery bypass graft surgery from 8 medical centers were measured in a cohort from the Northern New England Cardiovascular Disease Study Group between 2004 and 2007. We evaluated the association between preoperative and postoperative biomarkers and 1-year readmission or mortality using Kaplan-Meier estimates and Cox proportional hazards modeling, adjusting for covariates used in The Society of Thoracic Surgeons 30-day readmission model. RESULTS: The median follow-up time was 365 days. After adjustment for established risk factors, above-median levels of postoperative galectin-3 (median 10.35 ng/mL; hazard ratio, 1.40; 95% confidence interval, 1.08 to 1.80; p = 0.010) and N-terminal prohormone of brain natriuretic peptide (median = 15.21 ng/mL, hazard ratio, 1.42; 95% confidence interval, 1.07 to 1.87; p = 0.014) were each significantly associated with 1-year readmission or mortality. CONCLUSIONS: In patients undergoing cardiac surgery, novel cardiac biomarkers were associated with readmission or mortality independent of established risk factors. Measurement of these biomarkers may improve our ability to identify patients at highest risk for readmission or mortality before discharge. This will also allow resource allocation accordingly, while implementing strategies for personalized medicine based on the biomarker profile of the patient.
引用
- Jacobs JP, Alam SS, Owens SL, et al. The Association Between Novel Biomarkers and 1-Year Readmission or Mortality After Cardiac Surgery. Ann Thorac Surg. 2018. PMID: 29864407. doi:10.1016/j.athoracsur.2018.04.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。